Omri Amirav-Drory - The Biology Bet: Investing in What Comes Next

‍

‍

Omri Amirav-Drory on investing at the frontier of biology, longevity, and the technologies redefining what’s possible for human life.‍
‍

What happens to the way we build, lead and live when time itself stops being a fixed constraint?

In this episode of The Human Founder Longevity Series, I sit down with Omri Amirav-Drory — General Partner at NFX, scientist, two-time founder, biotech investor and Co-founder of Renewal Bio.

Beneath those titles is a much bigger mission: Omri wants to help end involuntary death.

He calls aging the “end boss” of the game of life and believes humanity may be approaching a new threshold in our ability to extend healthy human life.

For Omri, this is not a thought experiment about immortality. It is a scientific, entrepreneurial and deeply personal attempt to challenge something humanity has always treated as inevitable.

‍

Entrepreneurship as a Technology for Changing Reality

Omri has an unusual definition of entrepreneurship.

The best founders, he argues, can see a version of the world that does not yet exist. They become so dissatisfied with the gap between that possible future and current reality that they devote themselves to closing it.

They do not simply build companies. They pull reality toward a different future.

That belief has shaped Omri’s journey from biological research and his first startup, Genome Compiler, to investing in TechBio and building Renewal Bio. It also explains why he distinguishes between people who want to become entrepreneurs and those who feel they have to.

When the mission is significant enough, entrepreneurship becomes a vehicle for turning conviction into reality.

But Omri is far from romantic about what that requires. After five and a half years as a CEO, he describes the founder’s journey as extraordinarily difficult. The same realism guides his work as an investor: most early-stage companies will fail, ideas will change, and luck plays a larger role than many people are comfortable admitting.

His worldview holds both ideas at once: clear-eyed realism about the odds and enough optimism to keep building anyway.

‍

Refusing to Accept the Inevitable

Omri’s interest in longevity became deeply personal when his father died from colon cancer at 69.

That loss intensified a conviction that had been forming for years: aging should not automatically be accepted as an immutable condition of human existence.

His idea of the “race to 160” represents a threshold rather than simply a target age. If science can extend healthy life significantly beyond today’s known limits, it may mean we have learned how to intervene in some of the fundamental mechanisms behind aging and age-related disease.

Instead of asking only how we can become more comfortable with mortality, Omri asks a radically different question:

What if we worked on the problem?

In our conversation, he maps some of the scientific paths that might move us closer to that future — from reprogramming and regeneration to replacement — and explains why creating young, genetically matched cells, tissues and potentially organs sits at the center of Renewal Bio’s work.

The possibilities are extraordinary. So are the scientific and ethical questions surrounding them.

The ability to imagine a different future does not remove the need for judgment. It makes that judgment even more important.

‍

Choosing a Problem Worth a Lifetime

Perhaps the most human moment in a conversation filled with futuristic science comes from Omri’s young daughter.

She has begun asking why people grow old and why people die. His answer is simple:

“I’m working on it.”

The sentence captures something essential about his worldview. Faced with mortality, his response is neither denial nor resignation. It is agency.

Omri knows that he may not complete this mission within his lifetime. Meaning, for him, comes from choosing a problem worthy of that lifetime, helping move it forward — and finding ways to enjoy the journey.

This is also where the conversation returns to the human questions behind technological ambition.

If longevity, AI and robotics continue advancing together, what happens to institutions built around much shorter lives? How might we rethink education, careers, retirement, relationships and the role of work? And if we gain more time, what will we actually choose to do with it?

These questions may sound futuristic, but they reveal something about the lives we are building today.

Which problems deserve our time? Which ambitions still matter when examined across a longer horizon? And what makes a life worth extending in the first place?

‍

Listen to the full episode with Omri Amirav-Drory for

‍

About Omri Amirav-Drory

Omri Amirav-Drory, PhD is a General Partner at NFX, scientist, entrepreneur and biotech investor. He previously founded Genome Compiler and is a co-founder of Renewal Bio. His work sits at the intersection of science, entrepreneurship and venture capital, with a particular focus on technologies that could reshape aging, disease and human lifespan.

‍

Read: The Race to 160

In The Race to 160, Omri expands on one of the central ideas in this episode: why radically extending healthy human lifespan could represent a threshold in our ability to intervene in aging itself — and why he believes entrepreneurs and scientists should treat aging as a problem worth working on.

Read The Race to 160

‍

About Renewal Bio

Renewal Bio, co-founded by Omri, is a biotech company exploring stem-cell-derived embryo models and their potential applications in regenerative medicine — bringing some of the radical longevity questions discussed in the episode into real-world scientific development.

‍

Further Reading: The Investor Case for Longevity

For those who want to explore the entrepreneurial and investment side of the conversation, Omri has written extensively about the transition from treating disease to developing technologies designed to keep healthy people healthy.

The Future of Longevity: Keeping Healthy People Healthy — NFX

Why Don’t Billionaires Invest in Longevity? — NFX
‍

Continue the Conversation

If this conversation resonated with you, we invite you to continue the journey with us:

📩 Join The Human Founder newsletter for deeper reflections, founder stories, and behind-the-scenes insights on leadership, resilience, longevity, and the entrepreneurial journey.

📖 Explore my book, The Human Founder: How to Build a Startup and Stay Alive, where I go deeper into many of the questions at the heart of this conversation: how to sustain ambition over time, navigate the emotional realities of entrepreneurship, and build without losing the human being behind the company.

🎙️ Listen to the full episode and join us as we continue exploring the intersection of leadership, health, resilience, technology, and long-term human performance.

‍

About the Longevity Series

The Human Founder’s Longevity Series explores what happens when we expand the founder's conversation beyond mental resilience and performance to include the body, healthspan and the systems that allow us to perform, lead and live well for longer.

The series brings together founders, investors, researchers and practitioners to explore the science, technology, business and human questions behind one of the most consequential shifts in health.

The Longevity Series is created in collaboration with Welltech Ventures, Hunter Executive Search and LeumiTech.

‍